drugset / Trial / NCT02448914

A Study to Compare Plasma Levels of Levodopa, Carbidopa and Entacapone After TRIGEL or Duodopa Infusion in PD Patients

NCT02448914

RandomizedCrossoverOpen-labelTreatment

Summary

This study evaluates the continuous addition of entacapone to infused levodopa and carbidopa on the pharmacokinetic (PK) profile in patients with advanced Parkinson's disease (PD). All patients will receive both study drugs, i.e. TRIGEL (levodopa, carbidopa, and entacapone) and Duodopa (levodopa and carbidopa), in randomized order.

Timeline

Start
2015-05
Primary completion
2015-07
Completion
2015-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Carbidopa Unknown 5 mg/ml Other
Subject Entacapone Small molecule 20 mg/ml Other
Subject Levodopa Small molecule 20 mg/ml Other

Indications